Neutrophil percentages in bronchoalveolar lavage fluid: Implications for diagnosing bacterial pneumonia in patients with immunocompromise and neutropenia

Kevin M. Grudzinski; Samuel Fenske; Alec Peltekian; Nikolay S. Markov; Anna Pawlowski; Mengjia Kang; James M. Walter; Chiagozie I. Pickens; Nandita R. Nadig; Ankit Agrawal; Benjamin D. Singer; Richard G. Wunderink; Catherine A. Gao; NU SCRIPT Study Investigators

doi:10.1101/2024.05.04.24306709

Abstract

Rationale Pneumonia is the most common infection in ICU patients and a leading cause for death. Assessment of bronchoalveolar lavage fluid (BALF) cellularity can aid in pneumonia diagnosis. Low percentages (<50%) of BALF neutrophils have a high negative predictive value for bacterial pneumonia in a general medical ICU population. The operating characteristics in patients with immunocompromise and neutropenia are less clear.

Objective To compare BALF % neutrophils operating characteristics in patients with and without immunocompromise or neutropenia.

Methods This was a single center observational cohort study. Patients were categorized into three groups: (1) patients with neutropenia, (2) patients with underlying immunocompromise, and (3) patients with neither. BAL-level analysis reflected neutropenia and immunocompromise state on day of BAL sampling. Operating characteristics of BALF % neutrophils were calculated using varying thresholds of alveolar neutrophilia. Median [Q1,Q3] are reported for nonparametric data and compared using Mann-Whitney U tests.

Results 688 mechanically ventilated patients had 1736 BAL samples. Among bacterial pneumonia episodes, no difference was found in BALF % neutrophils between patients with underlying immunocompromise and patients with neither neutropenia nor immunocompromise on day of sampling: 82.0% [61.0, 91.0] vs 81.0% [66.0, 91.0], p=0.859. However, when neutropenic on day of sampling, the median BALF % neutrophils was 35.0% [8.8, 67.5] (p<0.001 compared with other categories). In patients with neutropenia, a BALF % neutrophil threshold of 7% had a sensitivity of 90% for excluding bacterial pneumonia.

Conclusions We found that among patients with bacterial pneumonia, BALF % neutrophil was not significantly lower in patients with a broad spectrum of immunocompromised states but was significantly lower when measured during acute neutropenia. We found varying thresholds of BALF % neutrophils across the three groups. Patients with neutropenia who mount even a low percent of alveolar neutrophils should raise concern for bacterial pneumonia.

Competing Interest Statement

BDS holds US patent 10,905,706, “Compositions and methods to accelerate resolution of acute lung inflammation,” and serves on the scientific advisory board of Zoe Biosciences, in which he holds stock options. Other authors have no conflicts within the area of this work.

Funding Statement

SCRIPT is supported by NIH/NIAID U19AI135964. Work in the Division of Pulmonary and Critical Care is also supported by SQLIFTS and the Canning Thoracic Institute. NSM is supported by AHA 24PRE1196998. RGW is supported by NIH grants (U19AI135964, U01TR003528, P01HL154998, R01HL14988, and R01LM013337). BDS is supported by the NIH (R01HL149883, R01HL153122, P01HL154998, P01AG049665, U19 AI181102, and U19AI135964). CAG is supported by NIH/NHLBI K23HL169815, a Parker B. Francis Opportunity Award, and an American Thoracic Society Unrestricted Grant. The funding sources did not have a role in the design, execution, or prior review of the study or in the data presented in this manuscript. Opinions expressed in this work do not necessarily reflect those of the funding sources.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the Northwestern University Institutional Review Board with study ID STU00204868.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Footnotes

Funding: SCRIPT is supported by NIH/NIAID U19AI135964. Work in the Division of Pulmonary and Critical Care is also supported by SQLIFTS and the Canning Thoracic Institute. NSM is supported by AHA 24PRE1196998. RGW is supported by NIH grants (U19AI135964, U01TR003528, P01HL154998, R01HL14988, and R01LM013337). BDS is supported by the NIH (R01HL149883, R01HL153122, P01HL154998, P01AG049665, U19 AI181102, and U19AI135964). CAG is supported by NIH/NHLBI K23HL169815, a Parker B. Francis Opportunity Award, and an American Thoracic Society Unrestricted Grant. The funding sources did not have a role in the design, execution, or prior review of the study or in the data presented in this manuscript. Opinions expressed in this work do not necessarily reflect those of the funding sources.
Declarations of interests: BDS holds US patent 10,905,706, “Compositions and methods to accelerate resolution of acute lung inflammation,” and serves on the scientific advisory board of Zoe Biosciences, in which he holds stock options. Other authors have no conflicts within the area of this work.
Human Ethics and Consent to Participate: This study was approved by the Northwestern University Institutional Review Board with study ID STU00204868. Study participants or their surrogates provided informed consent.
Data availability: A significant portion of this data has been already made available through PhysioNet at https://physionet.org/content/script-carpediem-dataset/1.1.0/, a future update will include new patients and updated data since the publication of the original dataset. Code associated with this project is available at https://github.com/NUSCRIPT/grudzinski_neutropenia_2024.
Additional analysis including breakdown by BALs, additional authors.

Data Availability

A significant portion of this data has been already made available through PhysioNet at https://physionet.org/content/script-carpediem-dataset/1.1.0/, a future update will include new patients and updated data since the publication of the original dataset.

https://physionet.org/content/script-carpediem-dataset/1.1.0/

Abbreviations List

(ICU): Intensive care unit
(BALF): bronchoalveolar lavage fluid
(NBBAL): non-bronchoscopic BAL
(ANC): absolute neutrophil count
(NPV): negative predictive value
(PPV): positive predictive value
(+LR): positive likelihood ratio
(-LR): negative likelihood ratio
(CAP): community associated pneumonia
(HAP): hospital associated pneumonia
(VAP): ventilator associated pneumonia

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.